Osteopore’s CTO Lim Jing will take on a new chief operations role as the medtech moves to expand its position as a global leader in bone regeneration.  

Bone healing specialist Osteopore (ASX:OSX) has announced its chief technology officer (CTO) Dr Lim Jing has been appointed chief operating officer.

Jing will take up the newly appointed position on May 1 and be responsible for overseeing the daily business and administrative operations, assessing, and enhancing efficiency of internal and external operational processes.

Jing will also collaborate with management and other stakeholders to identify initiatives to increase the value of Osteopore.


In Vivo 30 Rising Leaders for 2022

With more than a decade of experience in tissue engineering research and a deep understanding of Osteopore’s novel technology, Jing will  continue his role as CTO.

Under this structure, Jing’s operational scope will expand to allow for the increased use of Osteopore’s tissue regeneration technology across new applications and accelerate development of next generation implants to access multi-billion markets.

Jing has been selected as one of the ‘In Vivo 30 Rising Leaders for 2022,’ a global listing of leaders challenging traditional structures across the biopharma and medtech sectors.

Jing’s outstanding track record of commercialising Osteopore’s breakthrough products and success in achieving global regulatory approval as well as here in the APAC region.

Dedication to Osteopore vision

Osteopore CEO Goh Khoon Seng said Jing has consistently demonstrated technical expertise, strong leadership, and dedication to the company’s commercial vision.

“He has been instrumental in improving our underlying technology and manufacturing processes,” Seng said.

“This new role will be critical in executing additional collaborative partnerships, gaining further regulatory clearances, and launching complementary products for additional bone regeneration applications.”

Earlier this month Osteopore expanded its footprint in Europe with a maiden shipment of its cranial (skull) regenerative implants to Spain.

The medtech has also sent maiden shipments to Colombia.

This article was developed in collaboration with Osteopore, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.